Two studies demonstrate effectiveness of retapamulin to treat impetigo

摘要

Topical retapamulin was effective in clearing impetigo lesions in two studies, according to a meeting poster. "Impetigo is a common skin infection mainly in children, primarily cased by Staph-ylococcus aureus," Theodore Rosen, MD, of the department of dermatology at Baylor College of Medicine, and colleagues wrote. Retapamulin 1% is an FDA-approved topical antibacterial agent to treat impetigo in those older than 9 months of age. The first study, a randomized, double-blind, multicenter, placebo-controlled trial, included 139 subjects treated with retapamulin and 71 treated with placebo. Each treatment was applied two times a day for 5 days.